Monday, January 11, 2021
INTRODUCTION
The pharmaceutical and life sciences industry has been at the center of public discussion this year like never before due to the COVID-19 pandemic. The role of the industry has been crucial not only in developing potential treatments or vaccines for COVID-19 but also in ensuring that drug supplies for other disorders remain uninterrupted. The drug regulator has also acted quickly and decisively during this pandemic to ensure that pharmaceutical companies get the support they need to be able to maintain a steady supply of medicines.
In this pharma wrap, we have summarized the key regulatory developments that took place over 2020.